Krikorian Lazarus, an officer at Cencora, Inc., has reported the sale of 986 shares of the company’s stock. The shares were sold at a price of $330.96 each on November 2, 2026. This transaction is notable as it highlights ongoing adjustments within the leadership at Cencora, a key player in the wholesale-drugs industry.

Cencora, Inc., formerly known as AmerisourceBergen Corp, operates in the wholesale-drugs sector. The company is based in Conshohocken, Pennsylvania, and is incorporated in Delaware. Cencora is listed under the Central Index Key (CIK) number 0001140859.

According to the SEC filing, Lazarus's transaction was categorized as a disposal of shares, with a total of 986 shares sold. Following this transaction, he retains ownership of 14,197 shares of Cencora. The filing indicates that Lazarus holds the position of Senior Vice President and Chief Accounting Officer at the company.

This stock sale may have implications for Cencora's investor relations and overall market perception. As the wholesale-drugs industry continues to evolve, such transactions by company officers may signal shifts in strategy or confidence in company performance.

The filing does not specify what actions will follow this transaction.

Company Overview and Background

Cencora, Inc. operates under the Central Index Key (CIK) number 0001140859 and is classified under the Standard Industrial Classification (SIC) code 5122, which pertains to wholesale-drugs proprietaries and druggists' sundries. This classification highlights the company's focus on distributing pharmaceutical products and related services.

The company is incorporated in Delaware and has its business address at 1 West First Avenue, Conshohocken, Pennsylvania, with a fiscal year ending on September 30. Cencora's business operations are vital to the healthcare supply chain, providing essential products to various healthcare providers.

Reporting Details

The SEC filing indicates that the transaction was reported on November 3, 2026, with the transaction date being November 2, 2026. The filing was categorized under Form 4, which is used to report the transactions of company insiders. The transaction code for this sale is marked as 'S', indicating a sale of shares.

"This filing underscores the regulatory requirements for transparency in insider trading activities, ensuring that shareholders are informed of significant transactions by company executives."

Additionally, the filing was signed by Elizabeth S. Campbell, who acted as attorney-in-fact for Lazarus Krikorian, reflecting the legal formalities involved in such disclosures.